Figure 7.

Miat promotes Sox4 expression by targeting miR-130b-3p in vitro

(A) The levels of miR-130b-3p in the plasma from healthy controls (n = 22, −0.8066 ± 0.4477) and clinical patients with DN (n = 61, −1.124 ± 0.4351). (B) A luciferase reporter assay was performed to evaluate the interaction between miR-130b-3p and Miat in HEK293 cells (n = 3). (C) RIP revealed the interaction of Miat and miR-130b-3p in podocytes (n = 3). (D) Real-time PCR revealed the expression of miR-130b-3p in podocytes in the presence of miR-130b-3p mimic and Miat-WT plasmid or Miat-MUT plasmid (n = 3). (E) Dual-luciferase reporter assay showed the interaction between miR-130b-3p and the Sox4 3′ UTR in HEK293 cells (n = 3). (F) Western blotting manifested the expression of Sox4 in podocytes after pretreatment with the miR-130b-3p mimic (n = 3). (G) Real-time PCR revealed Sox4 mRNA expression in podocytes (n = 5). (H) Western blotting was used to assess Sox4 expression in different groups of podocytes (n = 3). EV, empty vector. (I) The expression of Sox4 in podocytes was revealed by western blotting (n = 3). (J) The expression of Sox4 was measured in podocytes using western blotting (n = 3). Error bars represent ±SD. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.